Bridging Treatment Gaps in the Management of Hypoactive Sexual Desire Disorder

INTENDED AUDIENCE

OB/GYNs, urologists, primary care physicians, endocrinologists, nurses with focus in reproductive/sexual medicine, NPs/PAs, psychologists/sex therapists, residents/fellows of above disciplines, managed care clinicians, and clinical pharmacists interested in management and treatment of HSDD.

STATEMENT OF NEED

Sexual health is an integral component of women's psychological and overall physical health. Clinicians often perceive the treatment of female sexual health as a quality of life issue and low health priority; furthermore, they often do not believe they possess the knowledge and experience to diagnose and manage hypoactive sexual desire disorder (HSDD). A lack of bidirectional patient-physician communication is a significant reason HSDD remains undertreated: patients are reluctant to discuss sexual concerns with their physicians, and physicians are reluctant to inquire about sexual health. Furthermore, some physicians are concerned that conversations about sexual function are too time-consuming during the office visit. Because physicians play a key role in providing education on sexual health, assessing patients for HSDD, and determining appropriate treatment, it is critical for all clinicians to recognize the importance of addressing sexual health, consistently incorporating screening tools designed to ascertain the precise etiology of female sexual dysfunction (FSD); educational strategies should be utilized to overcome perceived time constraints, improve diagnostic skills and facilitate open, communication with patients about sexual function.

EDUCATIONAL OBJECTIVES

Patient outcomes could be measurably improved if physicians were better able to…

1. Define and differentiate between FSD and HSDD through careful use of screening questionnaires, assessment, and physical examination, to ensure proper diagnosis and successful nonmedical and medical treatment outcomes
2. Recognize the level of distress HSDD and sexual dysfunction has on each patient's overall health and well-being
3. Encourage each woman to engage in discussions of sexual health with her doctor, to determine "normal" sexual function and dysfunction for her
4. Select appropriate treatment based on available FDA-approved treatment options, patient's treatment goals, and the degree to which the patient wants sexual function restored
5. Evaluate and proactively manage adverse events of HSDD medications and modalities to allay patient concerns about side effects and ensure therapeutic persistence

ACCREDITATION AND CERTIFICATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CogniMed Inc and Dannemiller. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians. Dannemiller designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s) 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the posttest and evaluation to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail cme@dannemiller.com.

Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229. This activity has been approved for 1.0 contact hours. CBRN credit is not accepted by the Michigan and Utah State licensing boards.

Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. It provides 1.0 of continuing education.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

CONTENT REVIEW STATEMENT

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

DISCLOSURE STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.

Dannemiller
Mark T. Nadeau, MD, MBA, FAAFP, Clinical Content Reviewer, has nothing to disclose.
Gloria Herrera, RN, MSN, FNP-BC, Nurse Practitioner Content Reviewer, has nothing to disclose.
Gordon Ringler, Project Manager, has nothing to disclose.

CogniMed Inc Staff
Estelle Perera, Senior Director, Scientific Affairs and Program Design, has nothing to disclose.
Nancy Vogel, Production Editor, has nothing to disclose.

Co-Chairs
Sheryl Kingsberg, PhD, is a consultant to/on the advisory boards of Apricus Biosciences; Emotional Brain; Novo Nordisk; Palatin Technologies; Pfizer, Inc; Shionogi Inc; Sprout Pharmaceuticals; SST; and Teva Pharmaceutical Industries Ltd. She is an investigator for Palatin Technologies; Shiongoi Inc; and Sprout Pharmaceuticals; and is a stockholder of Viveve.

James A. Simon, MD, is on the speakers' bureaus of Amgen Inc; Eisai, Inc; Merck; Noven Pharmaceuticals, Inc; Shionogi Inc; and Teva Pharmaceutical Industries Ltd; is a consultant to/on the advisory boards of AbbVie, Inc; Actavis, PLC; Amgen Inc; Apotex, Inc; Ascend Therapeutics; Depomed, Inc; Everett Laboratories, Inc; Lupin Pharmaceuticals; Therapeutics MD; Meda Pharmaceuticals Inc; Merck & Co, Inc; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals, Inc; Novo Nordisk; Pfizer Inc; Shionogi Inc; Shippan Point Advisors LLC; Sprout Pharmaceuticals; and Teva Pharmaceutical Industries Ltd; and has received grants/research support from AbbVie, Inc; Actavis, PLC; EndoCeutics Inc; Novo Nordisk; Novogyne; Palatin Technologies; and Teva Pharmaceutical Industries Ltd.

Faculty
Stanley E. Althof, PhD, is a speaker for Menarini; is a consultant to/on the advisory boards of AbbVie; Allergan; Eli Lilly and Company, Ixchelsis; Palatin Technologies; Plethora; and Sprout Pharmaceuticals; and is an investigator for Allergan; Palatin Technologies; and Trimel Pharmaceuticals.

Anita H. Clayton, MD, is a consultant to/on the advisory boards of Arbor Scientia; Euthymics Bioscience; Forest Laboratories; Lundbeck Inc; Palatin Technologies; S1 Biopharma; Sprout Pharmaceuticals; and Takeda Pharmaceuticals North America; is an investigator for Forest Laboratories; Pfizer Inc; Takeda Pharmaceuticals North America; and Trimel Pharmaceuticals; and is a stockholder for Euthymics; and S1 Biopharma.

Irwin Goldstein, MD, is a speaker for Ascend Therapeutics; is a consultant to/on the advisory boards of Apricus Biosciences, Emotional Brain, ExploraMed, Sprout Pharmaceuticals, and Strategic Science & Technologies; and is an investigator for Apricus Biosciences, and ExploraMed.

Susan Kellogg-Spadt, CRNP, PhD, is a speaker for Neogyn Inc; Novo Nordisk; and Shionogi Inc; and is a consultant to Neogyn Inc; Novo Nordisk; Shionogi Inc; and Sprout Pharmaceuticals.

Michael Krychman, MD, is on the speakers' bureaus of Noven Pharmaceuticals, Inc; Palatin Technologies; Pfizer Inc; Shionogi Inc; and Sprout Pharmaceuticals; and is a consultant to/on the advisory boards of Bayer Healthcare Pharmaceuticals Inc; Noven Pharmaceuticals, Inc; Palatin Technologies; Pfizer Inc; Shionogi Inc; and Sprout Pharmaceuticals.

Sharon J. Parish, MD, is a consultant to/on the advisory boards of Apricus Biosciences; Emotional Brain; Pfizer, Inc; Shionogi Inc; and Strategic Science & Technologies.

David Portman. MD, is on the speakers' bureaus of Noven Pharmaceuticals; Pfizer Inc; and Shionogi Inc; is a consultant to/on the advisory boards of Actavis; Noven Pharmaceuticals; Palatin Technologies; Pfizer Inc; Shionogi Inc; Sprout Pharmaceuticals; Teva Pharmaceutical Industries Ltd; and is an investigator for Actavis; Noven Pharmaceuticals; Palatin Technologies; Pfizer Inc; Shionogi Inc; and Trimel Pharmaceuticals.

Raymond C. Rosen, PhD, is a consultant to/on the advisory boards of Apricus Biosciences, Palatin Technologies, and Sprout Pharmaceuticals.

Off-label statement
Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of CogniMed Inc, Dannemiller, or Sprout Pharmaceuticals, Inc. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive on the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely on the information contained within this educational activity.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Jointly provided by

and

This activity is supported by an independent educational grant provided by Sprout Pharmaceuticals.

Next to Posttest and Evaluation >